#liraglutide

1 article tagged #liraglutide.

Editorial lifestyle photograph of official documents on an oak desk illustrating a regulatory proposal
NewsNews & PipelineMay 8, 20267 min read

FDA Proposes Permanent 503B Compounding Ban for Semaglutide, Tirzepatide & Liraglutide

Verified May 8, 2026: On April 30, FDA proposed permanently removing semaglutide, tirzepatide, and liraglutide from the 503B outsourcing bulk list — forever, not just during shortage enforcement. Public comment closes June 29, 2026. If finalized, no 503B pharmacy could bulk-compound these GLP-1 drugs in the future, even if a new shortage is declared. 503A patient-specific compounding under medical-necessity remains unaffected.

Top Picks

Four programs our readers click through most.

Eden Health GLP-1

8.9/10
$249/mo·Brand & Compounded

Embody

7.3/10
$299/mo·Compounded

Gala

7.2/10
$149/mo·Brand & Compounded

Enhance MD

7.8/10
$212/mo·Brand & Compounded

Affiliate links — we earn a commission at no extra cost to you. Selection reflects what readers convert through, not editorial endorsement. Full ranking + methodology at glp1picks.com.